This inventor holds 11 USPTO granted patents and 2 EPO patents. Top assignees: Merck Patent Gmbh, Biovation Limited. Active years: 2005-2011.
Location History:
- Aberdeen, GB (2005 - 2008)
- By Newmachar, GB (2006 - 2011)
Company Filing History:
Years Active: 2005-2011
Title: Graham Carter - Innovator in Immunology and Protein Therapeutics
Introduction
Graham Carter is a notable inventor based in Newmachar, GB. He has made significant contributions to the fields of immunology and protein therapeutics. With a total of 11 patents to his name, Carter's work focuses on developing therapeutic proteins that are less likely to elicit an immune response in humans.
Latest Patents
Carter's latest patents include innovative methods for reducing the immunogenicity of polypeptides. This invention aims to modify therapeutic proteins, specifically polypeptides, to minimize their propensity to trigger an immune response when administered to human subjects. The modifications involve introducing protease cleavage sites, attaching different molecules, or inserting non-natural amino acids. Another significant patent involves artificial modified proteins, particularly fusion proteins, which exhibit reduced immunogenicity compared to their non-modified counterparts. These novel immunoglobulin fusion proteins consist of an immunoglobulin molecule covalently fused to a biologically active non-immunoglobulin molecule. The invention also includes a method for creating such fusion proteins by identifying T-cell epitopes through computer-aided calculations.
Career Highlights
Throughout his career, Graham Carter has worked with prominent companies such as Merck Patent GmbH and Biovation Limited. His expertise in immunology and protein therapeutics has positioned him as a valuable asset in the field.
Collaborations
Carter has collaborated with notable individuals, including Anita Anne Hamilton and Francis Joseph Carr. These partnerships have contributed to the advancement of his research and innovations.
Conclusion
Graham Carter's contributions to immunology and protein therapeutics through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in therapeutic proteins that are safer for human administration.